NCT07033026

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 136 (estimated)
• Sponsor: NGM Biopharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Detailed description

Evaluation of Efficacy, Safety and Tolerability of NGM120 in a Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Participants with Colorectal Cancer who have Cancer Cachexia

Conditions

• Colorectal Cancer
• CRC (Colorectal Cancer)
• Cancer Cachexia

Interventions

Type	Name	Description
DRUG	NGM120 Q4W	NGM120 given subcutaneously every 4 weeks
DRUG	NGM120 Q8W	NGM120 given subcutaneously every 8 weeks
DRUG	Placebo given	Placebo given subcutaneously every 4 weeks

Timeline

• Start date: 2025-06-25
• Primary completion: 2027-04-01
• Completion: 2027-12-01
• First posted: 2025-06-24
• Last updated: 2026-04-01

Locations

28 sites across 4 countries: United States, Georgia, South Korea, Taiwan

Regulatory

• FDA-regulated drug study